Safety and tolerability of different total neoadjuvant therapy strategies in patients with locally advanced rectal cancer. First-in-human, phase 1a, dose escalation study of BGB-B167, a CEA x 4-1BB ...

A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved ...

However, this therapy can also lead to severe, albeit treatable, side effects, such as cytokine release syndrome ... human tumor or effector cells: BM was flushed out of the femur and tibia of mice.